This article summarized the latest R&D progress of Fosaprepitant Dimeglumine, the Mechanism of Action for Fosaprepitant Dimeglumine, and the drug target R&D trends for Fosaprepitant Dimeglumine.

Takeda has shared positive initial results from its Phase 2b trial, on TAK-279, a selective, orally administered TYK2 inhibitor, which is assessed for its efficacy in treating active psoriatic arthritis.

This article summarized the latest R&D progress of Ephedrine Hydrochloride, the Mechanism of Action for Ephedrine Hydrochloride, and the drug target R&D trends for Ephedrine Hydrochloride.

Aptamers are short nucleotide sequences, typically DNA or RNA of 20 to 100 nucleotides.

This article summarized the latest R&D progress of Eliglustat, the Mechanism of Action for Eliglustat, and the drug target R&D trends for Eliglustat.

LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.

This article summarized the latest R&D progress of Doripenem, the Mechanism of Action for Doripenem, and the drug target R&D trends for Doripenem.

CSF-1 exerts its effects by binding to a receptor called colony stimulating factor 1 receptor (CSF-1R), also known as c-FMS, leading to a signaling pathway cascade.

This article summarized the latest R&D progress of Dihydroergotamine Mesylate, the Mechanism of Action for Dihydroergotamine Mesylate, and the drug target R&D trends for Dihydroergotamine Mesylate.

Phase 3 CheckMate-227 Trial's findings confirm enduring, extended survival with Opdivo combined with Yervoy with Metastatic Non-Small Cell Lung Cancer.

This article summarized the latest R&D progress of Diacerein, the Mechanism of Action for Diacerein, and the drug target R&D trends for Diacerein.

Due to the small molecular weight and gene specificity of saRNA, it can be used to enhance the expression of specific proteins (products of tumor suppressor gene or haploinsufficient genes).